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Canada
6Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine Research Center, Université de Montréal, Montréal,
Québec, Canada
Correspondence: Tianwei Ellen
Zhou, Centre de Recherche, Hôpital
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PURPOSE. Spectral-domain optical coherence tomography (SD-OCT) is widely used in clinical
ophthalmology and recently gained popularity in laboratory research involving small rodents.
Its noninvasive nature allows repeated measurements, thereby decreasing the number of
animals required. However, when used at a conventional dosage, xylazine (an a2-
adrenoceptor) can cause irreversible corneal calcification, especially among young rodents.
In the present study, we test whether corneal calcification associated with xylazine is
mediated by the a2-adrenoceptor.
METHODS. Our study tested Sprague-Dawley rats, Long-Evans rats, and CD-1 mice (postnatal
day [P]14). Retinal images were captured by SD-OCT. Quantitative PCR (qPCR) was used to
study gene expression, whereas receptor localization was examined by immunofluorescent
staining followed by confocal microscopy. Calcium deposits were detected via von Kossa
staining.
RESULTS. When used at dosages appropriate for adult animals, ketamine-xylazine anesthetics
led to a high rate of respiratory failure, increased apoptotic activity in the corneal epithelium,
and irreversible corneal calcification in P14 rat pups. Meanwhile, OCT image quality
decreased drastically as a result of corneal calcification among animals recovering from
anesthesia. a2-Adrenoceptor subtypes were highly expressed on P14, in line with rodents’
age-specific sensitivity to xylazine. Clonidine, a potent a2-adrenoceptor agonist, dose-
dependently induced corneal calcification, which could be prevented by an a2-adrenoceptor
antagonist.
CONCLUSIONS. These data suggest that a2-adrenoceptors contribute to corneal calcification in
young rodents. Therefore, we developed a suitable OCT imaging protocol for this cohort,
including a carefully tailored ketamine-xylazine dosage (60 mg/kg and 2.5 kg/mg,
respectively).
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Spectral-domain optical coherence tomography (SD-OCT), atechnology widely used to examine retinal pathologies in
humans, has revolutionized the practice of ophthalmology and
has become part of the standard care.1,2 Optical coherence
tomography also gained increasing popularity in laboratory
research involving small rodents. Based on low-coherence
interferometry, it provides high-resolution cross-sectional imag-
ing of ocular structures, allowing rapid and reliable repeated
measures of delicate retinal layers in rodents. Contrary to the
traditional histology techniques that require euthanizing
animals and extensive sample process time, the noninvasive
nature of OCT allows longitudinal studies of the same cohort,
thereby decreasing the number of animals and minimizing
intersubject variability.
Ketamine hydrochloride is a noncompetitive, centrally
acting, dissociative general anesthetic that provides amnesia,
analgesia, and immobility.3 Ketamine offers a wide margin of
safety in most species, as well as a residual analgesia following
anesthetic recovery. Meanwhile, xylazine provides additional
analgesia and muscle relaxation. As an agonist for a2
adrenoreceptor (a G protein–coupled receptor), xylazine
activates the inhibitory Gi/0 heterotrimeric G protein. Thus
far, three distinct subtypes of a2-adrenergic receptors, a2A,
a2B, and a2C, have been identified.4 The ketamine-xylazine (K-
X) combination is the most commonly used drug combination
for injectable anesthesia in small rodents.3
However, rodents, especially young pups (postnatal day
[P]14), receiving K-X at the conventional dose (85 and 5.0 mg/
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kg, respectively) rapidly exhibit corneal calcification akin to
human band keratopathy 5–8 and show higher mortality due to
acute toxicity.9,10 Although some studies have suggested that
activation of a2-adrenergic receptors by xylazine is responsible
for corneal calcification, the current evidence for causality
remains thin and cannot explain rodents’ age-specific sensitiv-
ity to xylazine. In addition, the molecular mechanism
underlying this problem has not been fully explored. Because
the laser of an OCT device requires a transparent path to reach
the retina, corneal calcification secondary to K-X anesthetics
renders the technique ineffective, greatly hindering the use of
OCT in longitudinal follow-ups. Therefore, in this study, we
aimed to elucidate the relation between a2-adrenergic
receptors and corneal calcification and to describe an
optimized anesthesia protocol for performing time course
OCT experiments using rodent pups.
MATERIALS AND METHODS
All experiments were performed in compliance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Anesthesia and Follow-Up Schedule
Ninety-six Sprague-Dawley rats, 27 Long-Evans (LE) rats, and 20
CD-1 mice were used in our study. All animals were P14. At
days 1 and 3 of the study, animals were anesthetized by
intramuscular (i.m.) injection of a combination of ketamine (K)
(Vetalar, DIN 01989529; Bioniche Animal Health, Belleville,
Ontario, Canada) at 60, 70, or 85 mg/kg and xylazine (X)
(Rompun, DIN 02169592; Bayer HealthCare, Mississauga,
Ontario, Canada) at 2.5 or 5.0 mg/kg. Optical coherence
tomography imaging was performed under anesthesia at three
time points: 5 minutes, 30 minutes (day 1), and 3 days later,
and slit-lamp corneal examination was performed on day 3.
Following recovery of spontaneous locomotion, all animals
were returned to their home cages. The Sprague-Dawley rats
were euthanized immediately after day 3 OCT scans and
histology studies were performed.
Optical Coherence Tomography
Time course SD-OCT (Spectralis OCT Plus; Heidelberg
Engineering GmbH, Heidelberg, Germany) with enhanced
depth imaging was carried out on all rats. The anesthetized
rats were placed on a horizontal platform in front of the OCT
device. Tropicamide 1% (Mydriacyl; Alcon Laboratories, Inc.,
Fort Worth, TX, USA) dilating drops were instilled in the
studied eye. Volume scans of 158 3 58 (seven B-scans 240 lm
apart, ART 100 frames including 768 A-scans) were carried out
in the rats’ right eyes, by convention. If the imaging was
rendered difficult due to rapid breathing or movement that
disrupted the eye tracker, the experimenter gently stabilized
the rat’s head, with light pressure. The eye tracker was
directed at the center of the eye, and all OCT scans were
obtained at the temporal side of the optic nerve (equivalent to
the human macula). To circumvent the central corneal plaque
when present (Fig. 1A), images were acquired through the
peripheral cornea.
Quantification of Image Quality
Signal-to-noise ratio was calculated for all images obtained by
OCT using MATLAB (The MathWorks, Inc., Natick, MA, USA).
The signal was defined as the 90th percentile of the intensities
displayed in the retinal scan. The noise was defined as the SD
of intensities and was computed from a square of constant size
cropped from the vitreous region of each image. The quality
indices were then analyzed for each study condition by 1-way
ANOVA using the optimal condition (i.e., 60 mg/kg Kþ2.5 mg/
kg X at 5 minutes) as a control.
Slit-Lamp Biomicroscopy
Corneal opacities were observed using a slit-lamp (Coherent
LDS10A; Coherent Medical Group, Palo Alto, CA, USA). The
rats were placed on a horizontal platform in front of the
biomicroscope. The cornea and anterior segment were
examined and photographed through the slit-lamp ocular.
Corneal Tissue Preparation
All eyes were enucleated, fixed in 4% paraformaldehyde for 1
hour at room temperature, and dehydrated in 30% sucrose
overnight at 48C. Corneas were then dissected and frozen in
Optimal Cutting Temperature medium (Tissue-Tek; Sakura
Finetek, Inc., Torrance, CA, USA). Samples were cut into 10-
lm-thick sagittal sections (Microm HM500O; Microm Laborg-
FIGURE 1. Typical corneal opacification observed 3 days after i.m. injection of ketamine 85 mg/kg and xylazine 5.0 mg/kg at P14. (A) Slit-lamp
photograph showing an opaque and vascularized cornea. (B, C) Print-screen images of OCT scan. The low quality is reflected by the blurred fundus
image and the granulated retinal scan.




a-2A adrenoreceptor Adrar F: AGTTCGCTCAACCCGGTCAT
R: CGAGTTCGGAGCGTCCAGG
a-2B adrenoreceptor Adrar1 F: GCAGAGGTCTCGGAGCTAA
R: GCCTCTCCGACAGAAGATA
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erate GmbH, Waldorf, Germany) and processed for immuno-
histochemistry.
von Kossa Staining for Calcium
Cryo-section samples were placed in 3% silver nitrate solution
(cat. no. 209139; Sigma-Aldrich Corp., St. Louis, MO, USA) and
exposed to sunlight or UV light for 30–60 minutes as
previously described.11 They were subsequently rinsed in
three changes of distilled water, placed in 5% sodium
thiosulfate (cat. no. 217247; Sigma-Aldrich Corp.) solution for
2 minutes, and rinsed again in three changes of distilled water.
Nuclear fast red (cat. no. 229113; Sigma-Aldrich Corp.) (5
minutes) was used to counterstain the nuclei.
Immunohistochemistry
Cryo-section samples were stained with primary antibodies
against cleaved caspase-3 antibodies (Cell Signaling Technolo-
gy, Danvers, MA, USA; at 1:500 dilution), neuron-specific b III
tubulin (R&D Systems, Minneapolis, MN, USA; at 1:400
dilution), and/or a2A-adrenoceptor (Santa Cruz Biotechnology,
Dallas, TX, USA; sc-1478 at 1:200 dilution). The slides were
then counterstained with 4,6-diamidino-2-phenylindole, dihy-
drochloride (DAPI; 0.1 lg/mL; Molecular Probes, Eugene, OR,
USA). Stained slides were examined under a confocal
microscope (Zeiss, Toronto, Ontario, Canada).
RNA Isolation and Quantitative Real-Time PCR
Xylazine is considered to be responsible for corneal calcifica-
tion in young rats by activating a2-adrenoceptors.5,6,8 Mean-
while, sodium-bicarbonate cotransporter-1 (NBC-1) was linked
to corneal calcification associated with proximal renal tubular
acidosis.12 To evaluate whether the increased sensitivity to
xylazine in rat pups (P14) would be due to developmental gene
expression differences for a2-adrenoceptors (a2A, a2B, a2C;
gene symbols: Adrar, Adrar1, and Adrar2, respectively) and/or
NBC-1 (gene symbol: Slc4a4), quantitative PCR (qPCR)
analyses were performed. Eyes were rapidly enucleated and
placed into a sterile petri dish resting on ice. The cornea was
dissected and processed for RNA extraction using TRIzol
(Invitrogen, Thermo Fisher Scientific Corporation, Carlsbad,
CA, USA), followed by treatment with DNase I (Qiagen, Hilden,
Germany) to remove any contaminating genomic DNA. The
DNase-treated RNA was then converted into cDNA using
Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase
(Invitrogen). Polymerase chain reaction primers targeting rats
were designed using National Center for Biotechnology
Information (NCBI) Primer Blast (Table 1). Quantitative
analysis of gene expression was generated using an ABI Prism
7700 sequence detection system and the SYBR Green Master
Mix Kit (Bio-Rad Laboratories, Hercules, CA, USA). Gene
expression was calculated relative to 18S universal primer pair
(Ambion, Thermo Fisher Scientific, Inc., Waltham, MA, USA)
expression using the DCt method.
Effects of Clonidine Hydrochloride, Yohimbine
Hydrochloride, and Nifedipine
Clonidine hydrochloride (cat. no. C7897; Sigma-Aldrich Corp.)
was injected intramuscularly into P14 pups (N¼12; n¼3 pups
p[er group) with a dose varying from 0.075 to 0.600 mg/kg.
Three days later, pups were euthanized, and their corneas were
processed for cryo-section and histologic studies.
Nine P14 Sprague-Dawley rat pups received i.m. injection of
either xylazine (5.0 mg/kg), yohimbine hydrochloride (2.0 mg/
kg; cat. no. Y3125; Sigma-Aldrich Corp.) or xylazine þ
yohimbine (n ¼ 3 pups per group). For the last group,
yohimbine was administered 30 minutes after initial xylazine
injection. All pups were euthanized 24 hours after, and their
corneas were processed for qPCR or and histologic studies.
Six P14 Sprague-Dawley/LE rats and CD-1 mice received
topical nifedipine (an L-type calcium channel blocker; cat. No.
N7634; Sigma-Aldrich Corp.) 30 minutes after xylazine (5.0 mg/
kg) or xylazine (5.0 mg/kg)–ketamine (60 mg/kg) injections.
Nifedipine (20 lM) was applied topically on the cornea to avoid
severe adverse hemodynamic effects in young rodents. The time
at which corneal calcification was observed was recorded.















60 2.5 2 0/2 0/4
60 5.0 2 0/2 4/4
70 2.5 2 2/2 1/4
70 5.0 2 1/2 4/4
85 2.5 2 2/2 0/4
85 5.0 2 1/2 3/4










þ xylazine (5.0 mg/kg)
4 (2F, 2M) 0/3 7/8
Ketamine (60 mg/kg)
þ xylazine (2.5 mg/kg)
4 (2F, 2M) 0/3 0/8
Ketamine (60 mg/kg) 4 (1F, 3M) 0/3 0/8
Xylazine (5.0 mg/kg) 4 (2F, 2M) 0/3 8/8
Xylazine (2.5 mg/kg) 4 (1F, 3M) 0/3 1/8











þ xylazine (5.0 mg/kg)
4 (2F, 2M) 0/4 7/8
Ketamine (60 mg/kg)
þ xylazine (2.5 mg/kg)
4 (1F, 3M) 0/4 0/8
Ketamine (60 mg/kg) 4 (2F, 2M) 0/4 0/8
Xylazine (5.0 mg/kg) 4 (2F, 2M) 0/4 8/8
Xylazine (2.5 mg/kg) 4 (2F, 2M) 0/4 0/8














80 5.0 24 7/24 32/34
60 2.5 24 3/24 4 (from 3 rats)/48
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Statistical Analysis
Results are presented as means 6 SEM. 1-way or 2-way ANOVA
with significance (a ¼ 0.05) was used for processing data.
Bonferroni post hoc analysis was used for calculating
significance between groups. Two-tailed Student’s t-tests were
used to test for significance between two means.
RESULTS
Xylazine 5.0 mg/kg in P14 Young Rats Is Strongly
Associated With Irreversible Corneal Opacification
Twenty-four P14 Sprague-Dawley pups (initially destined to a
different experiment) were anesthetized using ketamine (85
mg/kg) and xylazine (5.0 mg/kg). Clear OCT fundus images
were obtained; however, seven young rats never recovered
from anesthetics and died (Table 2). On P21, all remaining 17
rats (10 males and 7 females) had developed a white, opaque,
chalky plaque in the central cornea of both eyes. In addition,
significant neovascularization extended from the limbal vascu-
lar plexus to the central cornea (Fig. 1A). Because OCT scans
could not proceed to completion due to low image quality
(Spectralis quality score < 10), sample images were obtained
via print screen (Fig. 1B). Similar corneal opacification induced
by xylazine (5.0 mg/kg) used alone or in combination with
ketamine was observed in CD-1 mice and LE rats (Tables 4, 5).
Identifying an Appropriate K-X Dose Combination
for Young Rats
A series of anesthetic combinations was then tested using
dosages within the ranges recommended by the National
Institutes of Health Office of Laboratory Animal Welfare13 (i.e.,
ketamine: 60–85 mg/kg; xylazine: 2.5–5.0 mg/kg; Table 3). All
tested combinations resulted in rapid onset of anesthesia
within 5–10 minutes, with noticeable muscle relaxation.
Three of four Sprague-Dawley rats that received 85 mg/kg
ketamine had irreversible respiratory failure (Table 3). The
remaining rat slowly regained consciousness after 4 hours but
appeared lethargic for another day. Similar observations held
true for pups that received ketamine at 70 mg/kg, except for a
slightly shorter duration before regaining consciousness and
full activity. All Sprague-Dawley/LE rats and CD-1 mice survived
with 60 mg/kg ketamine (Tables 3–7). Among SD rats, xylazine
at 5.0 mg/kg was strongly associated with the development of
corneal opacity (Table 3). Likewise, the majority of CD-1 mice
and LE rats receiving xylazine (5.0 mg/kg; alone or with
ketamine) showed corneal lesion (Tables 4, 5).
The K-X combination at 60 and 2.5 mg/kg was later used in
a separate experiment with 24 Sprague-Dawley rats (P14).
Three pups went into respiratory failure, and only four eyes
from three rats exhibited corneal opacification (Table 2). The
same regimen was also found to be relatively safe in CD-1 mice
and LE rats (Tables 4, 5).
Longitudinal OCT Imaging Using Ketamine 60 mg/
kg and Xylazine 2.5 mg/kg Yielded High-Quality
Images
Because corneal opacity appeared to be linked to xylazine
dosage in young rats (P14), we compared the OCT image
quality for two different xylazine dosages (group 1, 2.5 mg/kg
versus group 2, 5.0 mg/kg) using a constant dose of ketamine
(60 mg/kg) at different time points after injection (Fig. 2).
Five and 30 minutes after anesthetics injection, both groups
yielded high-quality OCT images, with clearly identifiable inner
nuclear layer (INL), outer nuclear layer (ONL), and choroid
(Ch) in all eyes (Figs. 2A–D).
On day 3, visual inspection and slit lamp confirmed white,
chalky corneal opacification in group 2 rats only (Fig. 2H). Day
3 OCT scans from group 1 rats (2.5 mg/kg xylazine; Fig. 2E)
were crisp compared with those from group 2 (5 mg/kg
xylazine; Fig. 2F), as confirmed by quality analyses (Fig. 2I). In
addition, OCT image acquisition for group 2 rats was much
more laborious as direct scanning was prevented by the
corneal plaque; we obtained only two scans by deviating the
laser beam through the peripheral cornea devoid of calcifica-
tion.
Histology Revealed Calcific Deposits and
Heightened Caspase-3 Activity in Affected Corneas
von Kossa staining of corneal sections of rats exposed to
higher-dose xylazine (group 2) revealed a thick dark band in
the anterior stroma and Bowman’s membrane (Fig. 3A) in all of
the animals, in line with the calcific deposit shown by the slit
lamp (Fig. 2H). In comparison, animals exposed to lower-dose
xylazine (group 1) showed normal cornea histology (Fig. 3B)
and slit-lamp appearance (Fig. 2G).
Cleaved caspase-3 signal in the surface squamous epitheli-
um of the cornea was observed in both groups (Figs. 3C, 3D).
However, only group 2 rats showed cleaved caspase-3–positive
columnar basal cells (Fig. 3D), which are the only corneal
epithelial cells capable of mitosis.14 Cleaved caspase-3 signal
was also sparsely observed in the anterior and mid-corneal
stroma of group 2 rats.
TABLE 7. Effects of Different Regimens on the Cornea of SD and LE Rats (P21)
Regimen
Number of Rats Number of Deaths Number of Eyes With Corneal Opacity
SD LE SD LE SD LE
Ketamine (60 mg/kg) þ xylazine (5.0 mg/kg) 6 (3F, 3M) 4 (2F, 2M) 0/6 0/4 0/12 3/8 (2 rats)
Ketamine (60 mg/kg) þ xylazine (2.5 mg/kg) 6 (3F, 3M) 4 (2F, 2M) 0/6 0/4 0/12 1/8
Ketamine (60 mg/kg) 4 (1F, 3M) 4 (1F, 3M) 0/4 0/4 0/8 0/8
Xylazine (5.0 mg/kg) 6 (3F, 3M) 4 (2F, 2M) 0/6 0/4 0/12 2/8 (1 rat)
Xylazine (2.5 mg/kg) 5 (2F, 3M) 4 (1F, 3M) 0/5 0/4 0/10 0/8















0 2.0 3 0/3 0/6
5.0 0 3 0/3 6/6
5.0 2.0 (30 minutes later) 3 0/3 0/6
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Expression of a2-Adrenoceptors, but Not NBC-1,
Are Elevated in Young SD Pups
Quantitative PCR analyses of a2-adrenoceptors (Adrar, Adrar1,
and Adrar2 genes) and NBC-1 (Slc4a4 gene) were performed.
They revealed that the expression of a2A- and a2B-adrenocep-
tors was significantly higher in the cornea of P14 rats (2.18-
and 3.20-fold, respectively) than at P21 (Figs. 4A, 4B); the a2C-
adrenoceptor was also highly expressed at P14 (Fig. 4C). The
expression level of NBC-1, however, did not change signifi-
cantly from P6 to P21 (Fig. 4D). In line with qPCR results,
confocal microscopy confirmed the colocalization of corneal
nerve fibers (labeled with bIII tubulin, red) and the a2A-
adrenoceptor (Figs. 4E, 4F) on corneal flatmounts.
Corneal Calcification in P14 SD Rats Is Dose-
Dependently Induced by Clonidine and Inhibited
by Yohimbine
To confirm the relation between a2-adrenoceptor and corneal
calcification, clonidine, an a2-adrenoceptor agonist more
potent than xylazine, was injected intramuscularly into P14
rats at increasing doses (0.075, 0.150, 0.300, or 0.600 mg/kg).
At 0.075 mg/kg, clonidine did not cause calcium deposit in
cornea, as indicated by the lack of von Kossa staining (Fig. 5A).
With a rising dose of xylazine, increasing amounts of calcium
(brown streaks) were detected in Bowman’s layer and anterior/
midstroma (Figs. 5B–D). Accordingly, corneal calcification
secondary to xylazine (5.0 mg/kg) was prevented by the a2-
adrenoceptor agonist yohimbine (2.0 mg/kg, intraperitoneally)
30 minutes after xylazine administration (Table 6; Figs. 5E–G).
Effect of Topical Nifidepin (20 lM) on Corneal
Calcification
Because activation of axonal a2-adrenoceptors decreases
neuronal excitation by blocking calcium influx,15 our original
hypothesis was that xylazine closes calcium channels, causing
buildup of extracellular calcium. Therefore, we used nifedipine
(topical drops, 20 lM), a potent L-type calcium channel
blocker, to see whether it is sufficient to induce corneal
calcification. Contrary to our expectation, nifedipine alone
does not induce corneal calcification in Sprague-Dawley/LE
rats or CD-1 mice. However, the drug seems to accelerate
corneal calcification (Fig. 6).
DISCUSSION
The K-X combination is widely used to anesthetize rodents.
Corneal calcification secondary to K-X anesthetics was first
reported in the 1980s. Calderone et al. reported ‘‘lens
opacification’’5 among rodents that received the K-X mix or
xylazine (13 mg/kg), but not ketamine alone. Two years later,
Guillet et al. demonstrated the problem was in fact calcification
of the cornea and suggested that anesthetic sensitivity is age
dependent.6 Using clonidine and yohimbine, Tita et al. and
Koehn et al. studied the relation between a2-adrenoceptors
and histologic alterations in rodent cornea.16,17 However, the
former did not study the composition of the corneal deposits.
In addition, neither paper explained why corneal calcification
is age dependent or explored the mechanism. A transparent
cornea is key to acquiring high-quality OCT imaging and
performing fundoscopy. Herein, we provide strong evidence to
relate rodents’ (in both rats and mice) age-specific sensitivity to
xylazine with corneal calcification. In this process, we also
optimized the protocol for repeated OCT measures.
A feature of this study is the expression profile of a2-
adrenoceptors: the mRNA levels of three subtypes simulta-
neously peaked at P14, coinciding with the timing of xylazine
toxicity (Figs. 4A–C). This is corroborated by confocal
microscopy showing colocalization of corneal nerve fibers
and a2-adrenoceptor (Figs. 4E, 4F). Along with previous
reports, corneal calcification is likely mediated through a2-
adrenoceptors based on the following observations: (1)
elevated a2-adrenoceptors expression in cornea of young pups
FIGURE 2. Comparing image quality of OCT scans obtained at 5
minutes, 30 minutes, and 3 days following administration of ketamine
60 mg/kg and xylazine 2.5 mg/kg (group 1) or 5.0 mg/kg (group 2) in
P14 pups. (A–F) Image quality at 5 and 30 minutes was comparable in
both groups, and OCT images revealed distinct and intricate retinal
structures. On day 3, three cases of irreversible corneal calcification
were observed in group 2 pups; as a result, OCT quality decreased
drastically (F). (G) Slip-lamp examination for group 1 was unremark-
able. (H) However, group 2 animals exhibited corneal opacification
similar to Figure 1A. (I) Quality analyses showed group 2 had
significantly lower image quality on day 3. OPL, outer plexiform layer;
Sc, sclera. *P < 0.05. Scale bar denotes 100 lm. N¼8; n¼4 per group.
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(P10 and P14) corresponds to the age for heightened xylazine
sensitivity (Fig. 1A; Table 2); (2) despite the use of a heating
pad and proper hydration, corneal calcification at P14 in rats
occurred within 1–2 hours after xylazine injection (i.m., 5.0
mg/kg)17 (the rapid onset of symptoms pointed toward a
receptor-mediated process); and (3) clonidine, a potent a2-
adrenoceptor agonist, dose-dependently induced corneal
calcification (Figs. 5A–D); whereas (4) yohimbine (an a2-
adrenoceptor antagonist) was able to prevent corneal calcifi-
cation in xylazine-treated pups (Figs. 5E–G).
The mechanism for a2-adrenoceptor–dependent calcifica-
tion remains unclear. Nifedipine accelerates corneal calcifica-
tion; yet the drug does not induce the problem (Fig. 6),
suggesting that the lack of calcium re-entry alone cannot
account for calcification. Other mechanisms, such as active
secretion of Ca2þ, may be involved.
In rodents, the density of corneal nerve fibers markedly
increases postnatally.18 During this period, nerve fibers
gradually form a swirl pattern near the apex of the cornea.19
As a result, the central cornea has the highest density of axon
terminals.20 This anatomical feature supports the observation
that corneal calcification is centrally located (Figs. 1A, 2H).
Thus far, mechanistic explanation for corneal calcification
remains scant. Usui etal. suggested the involvement of NBC-1, a
family of ion transporters linked to proximal renal tubule
acidosis12,21; NBC-1 is expressed in human cornea,22 and
mutations on this gene are postulated to cause ion imbalance
and, subsequently, corneal damages.12 However, we did not
find differential NBC-1 expression among young and adoles-
cent rodents (Fig. 4D). Hence, NBC-1 alone may not be
sufficient to account for rodents’ age-dependent sensitivity to
xylazine.6
Another notable observation in this study is the detection of
excessive apoptosis in corneal columnar basal cells in pups
that received the higher dose of xylazine (5.0 mg/kg) (Fig. 3D).
The upper squamous epithelium is known for orderly
apoptosis and desquamation as part of physiologic turnover.14
The columnar basal cells, however, are the only corneal
epithelial cells capable of mitosis23 (to replace apoptotic cells).
Increased cleaved caspase-3 activity in columnar basal cells
suggests a depletion of stem cell population in corneal
epithelium. This may explain the lack of sufficient corneal
repair following calcific injury.
Other anesthetic alternatives for OCT experiments have
been suggested. The most common alternative is isoflurane
inhalation using a rodent facemask.24,25 Although facemasks
have been redesigned over time, the frequent occurrence of
gas leakage still poses a hazard to personnel.24 In addition, the
bulkiness of the facemask and tubing is cumbersome, it
hinders proper alignment of the rodent eye with the OCT
FIGURE 3. Corneal opacification is linked to xylazine (5.0 mg/kg) in young rats. (A) Corneal opacification was observed 1–3 hours after i.m.
xylazine at 5.0 mg/kg in P14 rats. von Kossa staining revealed dense calcium deposit (brown-colored) at Bowman’s membrane and anterior stroma.
(B) In contrast, corneal calcification was avoided by lowering xylazine dosage to 2.5 mg/kg. Scale bar denotes 100 lm. (C, D)
Immunohistochemistry staining showed baseline, physiologic cleaved caspase-3 signals at the squamous cell layer of the epithelium. Pups
receiving xylazine at 5.0 mg/kg exhibited cleaved caspase-3 signals at both squamous and basal cell layers (yellow arrows). Scale bar denotes 20 lm.
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optical axis, and care must be taken to avoid contact with the
OCT’s objective lens, making it difficult to scan the desired
location. Last, K-X anesthetics offers better control on eye
movement (excessive movement decreases OCT quality) than
isoflurane.26 Thus, K-X remains a better option than inhalation
isoflurane in OCT acquisition.
Several external factors have been reported to be linked to
corneal calcification in the interpalpebral zone. Ocular surface
dryness resulting from tear evaporation27 leads to increased
concentration of ions such as calcium and phosphate. Carbon
dioxide release in this same zone also leads to pH eleva-
tion.28,29 Alkalinization facilitates the precipitation of calcium
phosphate, which already has low solubility and becomes
supersaturated in the fluids of the eye.8 The loss of body heat is
also considered a contributing factor to crystalline lens
opacification30 and calcium deposition in the cornea.17
However, in our study and that of Guillet et al.,6 lubricating
gel and warming pads failed to prevent corneal calcification
(Fig. 3A). Of note, because K-X combination reduces body
temperature and P14 pups still lack sufficient fur, all
anesthetized pups should be placed on warming pads until
they regained consciousness.
One caveat in this study is that only two strains of rats
(Sprague-Dawley and LE) and one stock of mice (CD-1) were
tested. However, Sprague-Dawley (albino)/LE (pigmented) rats
and CD-1 (albino) mice are outbred stocks (i.e., different
genetic makeup), yet their responses to xylazine (5.0 mg/kg)
were similar. Notably, C57BL/6J (inbred, pigmented),
C57BLKS/J (inbred, pigmented), and SJL/J (inbred, albino)
mice also suffer from corneal calcification following K-X.17
FIGURE 4. Gene expression levels of a2-adrenoceptors and NBC-1 in the cornea of rat pups (P6–P21). (A–C) Quantitative PCR analyses revealed the
expression of a2A- and a2B-adrenoceptors was significantly higher in the cornea of P14 rats (2.18- and 3.20-fold, respectively) than P21. In
particular, the a2A-adrenoceptor was most abundant on P10; the a2C-adrenoceptor had its highest expression on P14. (D) The expression pattern
of NBC-1, however, does not change significantly from P6 to P21. 18S was used as an internal control. All numbers were normalized by P6 values
(set as 1) (N¼ 16 rats; n¼ 4 rats per time point). (E) Immunohistochemistry staining on corneal flatmount revealed colocalization of nerve fibers
(bIII tubulin, red) and a2A-adrenoceptors (green). (F) Enlarged image showed the elongated shape of a nerve fiber with a2A-adrenoceptor
scattering on its axon. *P < 0.05. Scale bars denote 50 lm.
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Meanwhile, Wistar (inbred, albino), LE (outbred, pigmented),
and Fischer 344 (inbred, albino) rats are found to be more
susceptible to xylazine-induced corneal calcification than
Sprague-Dawley (outbred, albino) and Lewis (inbred, albino)
rats.8 This is in agreement with our data for P21 Sprague-
Dawley and LE rats (Table 7), although the two strains of rats
showed similar sensitivity at P14 (Tables 2, 5). Collectively, our
data suggest that sensitivity to xylazine is a general feature of
laboratory rodents: some stocks/strains may be more suscep-
tible; of note, all rodents tested by us and studies mentioned
above were wild-type animals. In this context, pigmentation
does not seem to alter susceptibility. Last, there does not seem
to be any sex predilection for xylazine-induced corneal
lesions.8
In conclusion, we hereby provide solid evidence that
corneal calcification in young rodents is likely mediated by a2-
adrenoceptors. Our study is relevant for longitudinal evalua-
tions of intraocular structures by OCT and other means as it
highlights the detrimental effects of corneal calcification; we
propose a new protocol to enable such longitudinal evalua-
tions including by OCT (Table 8).
FIGURE 5. Effects of clonidine and yohimbine in corneal calcification. (A–D) Corneal calcification associated with clonidine in P14 rats is dose
dependent. Postnatal 14 rats were injected with clonidine (an a2-adrenoceptor agonist more potent than xylazine) from 0.075 to 0.600 mg/kg. von
Kossa staining, in brown, demonstrated increasing amounts of calcium deposit in the cornea as xylazine doses rose. Scale bar denotes 100 lm. (E)
Yohimbine alone did not alter corneal histology. (F) Similar to previous experiments, corneal calcification was observed following xylazine (5.0 mg/
kg) injection. (G) However, yohimbine (2.0 mg/kg) administration 30 minutes after xylazine was able to prevent the problem. Sample sizes:
clonidine, N¼ 12, n¼ 3/group; yohimbine, N¼ 12, n¼ 3/group. Representative images from seven pups are shown. Scale bars denote 100 lm.
FIGURE 6. The effect of topical nifidepin (20 lM) in corneal calcification. (A–C) Different drug combinations were tested in SD/LE rats and CD-1
mice. Nifedipine alone and low-dose xylazine did not induce corneal calcification in any stain. Interestingly, nifedipine significantly accelerated
corneal calcification when used in conjunction with xylazine (5.0 mg/kg)-ketamine mix. X, xylazine; Nif, nifedipine; K, ketamine. *P < 0.05.
TABLE 8. Maisonneuve-Rosemont Hospital Protocol for High Caliber
OCT Retinal Images in Young (P14) Rats
1. Anesthesia: Ketamine 60 mg/kg and xylazine 2.5 mg/kg to
avoid animal demise and corneal calcification.
2. Pupil dilation: Tropicamide 1% (Mydriacyl; Alcon Laborato-
ries, Inc., Fort Worth, TX USA), one drop in the study eye.
3. Temperature: Keep anesthetized rat pups on warming
pads (35–378C) throughout the experiment and until they
regain full consciousness.31
4. Corneal hydration: Hydrate the cornea of the tested eye
every 12–15 seconds with PBS to allow clear fundus imag-
es and crisp OCT scans. A normal rat blinks about five
times per minute.32 Keep the unexamined eye constantly
covered with Tear gel (Alcon).
5. Restrained the head gently if rapid breathing interferes
with OCT acquisition.
6. Post-OCT precautions: both eyes should be covered with
tear gel until rats regain consciousness. Be mindful not to
have wood chips (from bedding) attached to their cornea.
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